Roots Analysis has done a detailed study on Global Autoinjectors Market (3^rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 600+ page report, which features 360+ figures and 350+ tables, please visit this link

 

Key Market Insights

• Currently, several companies claim to be engaged in the development / manufacturing of various types of autoinjectors, most of which are disposable systems that use prefilled syringes as primary drug containers
• About 90 autoinjector-based combination products have been approved for the treatment of a variety of clinical conditions; the subcutaneous route being the preferred mode of drug delivery via such devices
• In order to gain a competitive edge in the market, many autoinjector manufacturers are focusing on the integration of advanced features into their respective products and affiliated offerings
• Over time, more than 4,600 patents have been filed / granted related to autoinjectors and affiliated products; most of the new intellectual property is related to additional features, such as safety locks and device connectivity
• Eminent scientists from renowned organizations and academic institutions across the world have made valuable contributions to this field, in terms of leading clinical research efforts and developing novel technologies
• Several autoinjector developers have established strong brand positions in different geographies; the focus, in the near term, is likely to be on further enhancing device features for better disease management and improved patient compliance
• An evaluation of 200+ marketed and pipeline products revealed that a variety of drugs / product candidates are likely to be considered for administration via autoinjectors in the near future
• Case Study: Owing to the complexities associated with the manufacturing and assembly of autoinjector drug delivery systems, industry players are known to frequently engage the services of contract service providers
• Currently, disposable autoinjector products for small molecule drugs dominate the market; however, in the foreseen future, the demand for reusable devices is anticipated to witness significant growth
• Given the recent approvals and presence of multiple drug candidates in later stages of development, the market opportunity is likely to be distributed across different therapeutic areas, routes of administration and geographies

 

For more information, please visit  https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html

 

Table of Contents

 

1.              PREFACE

1.1.           Scope of the Report

1.2.           Research Methodology

1.3.           Chapter Outlines

 

2.              EXECUTIVE SUMMARY

                

3.              INTRODUCTION

3.1.           Chapter Overview

3.2.           Types of Drug Delivery Systems

3.3.           Drawbacks of Conventional Parenteral Delivery Systems

3.4.           Needlestick Injuries

3.4.1.        Incidence and Cost Burden

3.4.2.        Government Legislation for the Prevention of Needlestick Injuries           

                

3.5.           Emerging Trend of Self-Administration

3.5.1.        Rising Burden of Chronic Diseases

3.5.2.        Healthcare Cost Savings

3.5.3.        Need for Immediate Treatment in Emergency Situations

3.5.4.        Growth of Injectable Biologics Market

3.5.5.        Addressing Key User Safety Requirements

                

3.6.           Types of Self- Administration Devices

3.6.1.        Prefilled Syringes

3.6.2.        Pen-Injectors

3.6.3.        Needle-Free Injectors

3.6.4.        Autoinjectors

3.6.5.        Large Volume Wearable Injectors

                

3.7.           Overview of Autoinjectors

3.7.1.        Components of Autoinjectors

3.7.2.        Classification of Autoinjectors

3.7.2.1.      On the Basis of Mechanism of Action

3.7.2.2.      On the Basis of Usability

3.7.2.3.      On the Basis of Type of Dose

3.7.3.        Manufacturing / Packaging of Autoinjectors

3.7.4.        Benefits of Autoinjectors

                

3.8.           Regulatory Considerations

3.8.1.        Medical Devices

3.8.2.        Drug Device Combination Products

 

3.9.           Future Perspectives

                

4.              PRIMARY DRUG CONTAINERS

4.1.           Chapter Overview

4.2.           Types of Packaging

4.3.           Introduction to Primary Drug Containers

4.3.1.        Role of Primary Drug Containers

4.3.2.        Types of Primary Drug Containers

4.3.2.1.      Cartridges

4.3.2.1.1.   Components of Cartridges

4.3.2.1.2.   Types of Cartridges

4.3.2.1.2.1.  Single Chamber Cartridge

4.3.2.1.2.2.  Dual Chamber Cartridge

4.3.2.1.3.   Cartridges Available in the Market

                

4.3.2.2.      Syringes

4.3.2.2.1.   Components

4.3.2.2.2.   Types of Syringes

4.3.2.2.2.1.  Based on Number of Chambers

4.3.2.2.2.2.  Based on Type of Needle

4.3.2.2.3.   Prefilled Syringe Systems Available in the Market

4.3.2.2.3.1.  Glass Prefilled Syringes

4.3.2.2.3.2.  Plastic Prefilled Syringes

                

4.3.2.3.      Vials

4.3.2.3.1.   Components

4.3.2.3.2.   Vials Available in the Market

 

4.4.           Comparison of Fabrication Materials

                

5.              AUTOINJECTORS: CURRENT MARKET LANDSCAPE

5.1.           Chapter Overview

5.2.           Autoinjectors: List of Devices

5.2.1.        Analysis by Usability

5.2.2.        Analysis by Type of Primary Container

 

5.3.           Autoinjectors: List of Additional Parameters of Devices

5.3.1.        Analysis by Volume of Container

5.3.2.        Analysis by Type of Dose

5.3.3.        Analysis by Route of Administration

5.3.4.        Analysis by Actuation Mechanism

5.3.5.        Analysis by Type of Feedback Mechanism

                

5.4.           Autoinjectors: List of Developers

5.4.1.        Analysis by Year of Establishment

5.4.2.        Analysis by Company Size

5.4.3.        Analysis by Geographical Location of Headquarters

                

6.              PRODUCT COMPETITIVENESS ANALYSIS

6.1.           Chapter Overview

6.2.           Methodology

6.3.           Assumptions and Key Parameters

6.4.           Product Competitiveness Analysis

6.4.1.        Disposable Autoinjectors

6.4.2.        Reusable Autoinjectors

                

7.              BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS

7.1            Chapter Overview

7.2.           Scope and Methodology

7.3.           Brand Positioning Matrix: Antares Pharma

7.4.           Brand Positioning Matrix: BD

7.5.           Brand Positioning Matrix: DALI Medical Devices

7.6.           Brand Positioning Matrix: Elcam Drug Delivery Devices

7.7.           Brand Positioning Matrix: Oval Medical Technologies

7.8            Brand Positioning Matrix: Owen Mumford

7.9.           Brand Positioning Matrix: SHL Medical

7.10          Brand Positioning Matrix: Union Medico

7.11.         Brand Positioning Matrix: Ypsomed

                

8.              PATENT ANALYSIS

8.1.           Chapter Overview

8.2.           Scope and Methodology

8.3.           Autoinjectors: Patent Analysis

8.3.1.        Analysis by Application Year

8.3.2.        Analysis by Issuing Authority

8.3.3.        Analysis by CPC Symbols

 

8.4.           Emerging Areas

8.5.           Leading Players Based on Number of Patents

8.6.           Autoinjectors: Patent Benchmarking Analysis

8.6.1.        Analysis by Patent Characteristics

8.6.2.        Analysis by Geography

 

8.7.           Autoinjectors: Patent Valuation Analysis

                

9.              THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS

9.1.           Chapter Overview

9.2.           Autoinjector Combination Products: List of Approved Drugs

9.2.1.        Analysis by Initial Year of Approval

9.2.2.        Analysis by Usability

9.2.3.        Analysis by Route of Administration

9.2.4.        Analysis by Primary Drug Container

 

9.3.           Approved Autoinjector Combination Products: List of Additional Parameters

9.3.1.        Analysis by Type of Molecule

9.3.2.        Analysis by Dose Strength

9.3.3.        Analysis by Therapeutic Indication

9.3.4.        Analysis by Other Packaging Formats of Marketed Drugs

 

9.4.           Autoinjector Combination Products: List of Pipeline Drugs

9.4.1.        Analysis by Phase of Development

 

9.5.           Pipeline Autoinjector Combination Products: List of Additional Parameters

9.5.1.        Analysis by Route of Administration

9.5.2.        Analysis by Type of Molecule

9.5.3.        Analysis by Therapeutic Indication

9.5.4.        Grid Analysis: Distribution by Therapeutic Indication, Phase of Development and Route of Administration

                

9.6.           Autoinjector Combination Products: List of Developers

9.6.1.        Analysis by Year of Establishment

9.6.2.        Analysis by Company Size

9.6.3.        Analysis by Location of Headquarters

                

10.            CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS

10.1.         Chapter Overview

10.2.         Marketed / Pipeline Drugs Being Evaluated with Autoinjectors

10.3.         Case Study I: Anaphylaxis

10.3.1.       Overview and Epidemiology

10.3.2.       Adrenaline: Mechanism of Action

10.3.3.       History of Development

 

10.3.4.       Marketed Adrenaline / Epinephrine Autoinjectors

10.3.4.1.    Adrenaclick

10.3.4.2.    Allerject / Auvi-Q (Formerly called e-cue)

10.3.4.3.    Anapen

10.3.4.4.    Emerade

10.3.4.5.    EpiPen / EpiPen Jr

10.3.4.6.    Jext

10.3.4.7.    EpiPen / EpiPen Jr

 

10.3.5.       Adrenaline / Epinephrine Autoinjectors Under Development

10.3.5.1.    EpiQ

10.3.5.2.    ANDIPen

10.3.5.3.    MiniEpi

10.3.5.4.    Zeneo Adrenaline

 

10.3.6.       Other Dosage Forms

10.3.7.       Historical Sales of Approved Drugs / Autoinjectors

                

10.4.         Case Study II: Multiple Sclerosis

10.4.1.       Overview and Epidemiology

10.4.2.       Interferon β-1a

10.4.3.       Interferon β-1b

10.4.4.       Interferons: Mechanism of Action

10.4.5.       History of Development

 

10.4.6.       Interferon β-1a Autoinjectors

10.4.6.1.    Avonex Pen

10.4.6.2.    PLEGRIDY Pen

10.4.6.3.    Rebif Rebidose

10.4.6.4.    RebiSmart

10.4.6.5.    Rebiject II

10.4.6.6.    ReciGen Physioject

 

10.4.7.       Interferon β-1b Autoinjectors

10.4.7.1.    BETACONNECT

10.4.7.2.    BETAJECT Comfort / Betacomfort

10.4.7.3.    Betaject Lite

10.4.7.4.    ExtaviJect 30G / ExtaviPro 30G

 

10.4.8.       Other Marketed Autoinjectors

10.4.8.1.    Cinnomer40 Physioject

10.4.8.2.    CSYNC Autoinjector

10.4.8.3.    WhisperJECT

10.4.8.4.    Remurel Autoxon

 

10.4.9.       Other Dosage Forms

10.4.10.     Historical Sales of Approved Drugs / Autoinjectors

10.4.10.1.  Interferon β-1a

10.4.10.2.  Interferon β-1b

 

10.5.         Case Study III: Migraine

10.5.1.       Overview and Epidemiology

10.5.2.       Sumatriptan Succinate: Mechanism of Action

10.5.3.       History of Development

10.5.4.       Marketed Autoinjectors

10.5.4.1.    ALSUMA

10.5.4.2.    IMITREX STATdose Pen

10.5.4.3.    Zembrace SymTouch

10.5.4.4.    Aimovig SureClick Autoinjector

10.5.4.5.    Emgality Prefilled Pen

 

10.5.5.       Other Dosage Forms

10.5.6.       Historical Sales of Approved Drugs / Autoinjectors

                

10.6.         Case Study IV: Rheumatoid Arthritis

10.6.1.       Overview and Epidemiology

10.6.2.       History of Development

 

10.6.3.       Marketed Autoinjectors for Rheumatoid Arthritis

10.6.3.1.    Actemra

10.6.3.2.    CIMZIA AutoClicks Prefilled Pen

10.6.3.3.    Enbrel SureClick

10.6.3.4.    Hulio Prefilled Pen

10.6.3.5.    HUMIRA Pen

10.6.3.6.    ORENCIA ClickJect

10.6.3.7.    OTREXUP

10.6.3.8.    Rasuvo Autoinjector

10.6.3.9.    SIMPONI SmartJect Autoinjector

10.6.3.10.  KEVZARA Prefilled Pen

10.6.3.11.  IMRALDI Prefilled Pen

 

10.6.4.       Historical Sales of Approved Drugs / Autoinjectors

                

11.            LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS

11.1.         Chapter Overview

11.2.         Methodology and Key Parameters

11.3.         Marketed Drug Candidates for Delivery via Autoinjectors

11.3.1.       Most Likely Drug Candidates

11.3.2.       Likely Drug Candidates

11.3.3.       Less Likely Drug Candidates

11.3.4.       Unlikely Drug Candidates

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com